BioNet has been committed to developing, manufacturing and delivering vaccines.
BioNet is a pioneering biotechnology group specialising in the development of next-generation vaccines.
The group has grown rapidly and now comprises companies, experts and senior teams spanning the Asia-Pacific region, Europe and North America. Our team of over 200 individuals is united by a commitment to innovation and excellence in advancing global health.
Our scientists are passionate about shaping the future of vaccine development. Our Scientific Advisory Board, chaired by Professor Emeritus Stanley Plotkin, oversees our innovation programmes.
Drawing on its expertise in translational research, BioNet has become the leading producer of recombinant pertussis vaccines and has recently demonstrated its excellence by obtaining EU GMP certification.
For over 20 years, BioNet has been fostering partnerships to advance global health, making an impactful contribution to various immunisation programmes and global polio eradication initiatives. Together, we are working towards a healthier and safer world.
BioNet commits to develop and manufacture innovative high-quality vaccines that comply with applicable regulatory requirements.
BioNet’s Scientific Advisory Board (SAB) includes internationally recognized experts in vaccinology, infectious diseases, and immunology. Their strategic guidance ensures that our R&D remains at the forefront of scientific advancement.
Contact us and be part of the journey.
Our Location
Thailand
19 Soi Udomsuk 37, Bangkok 10260, Thailand
France
41 Cours de la Liberté 69003 Lyon Cedex 03, France
Social network